Is obesity a disease or a lifestyle choice? The answer people assume shapes whether your insurance covers treatment, how a doctor treats you, and how your family reacts when you start a GLP-1.
Where medicine stands
The American Medical Association formally recognized obesity as a disease in 2013, calling for a range of medical interventions to treat it (AMA policy H-440.842 (external link)). Other major medical bodies take the same view: obesity involves hormonal, genetic and physiological factors, not just willpower.
In 2025 a Lancet Diabetes & Endocrinology Commission of 58 experts, endorsed by 76 organizations, took a more precise approach (Rubino et al., 2025 (external link)). It splits the diagnosis in two. Clinical obesity is a chronic, systemic illness: excess body fat that is already impairing how organs or tissues work, or substantially limiting daily activities. Preclinical obesity is excess body fat with organ function still preserved, which carries a higher risk of illness but isn't itself an illness. The Commission also says BMI alone shouldn't be used to diagnose an individual. So it narrows the illness label compared with a blanket "obesity is a disease" position. It is just as firm that people with clinical obesity should get timely, evidence-based treatment, that policymakers should ensure fair access to it, and that weight bias and stigma are major obstacles to care.
That clinical view still hasn't reached insurance policy, workplaces or everyday conversation, where "just eat less and move more" is common.
Where the framing shows up
Coverage. Coverage rules carry an implicit judgment about what's worth paying for. Medicare's exclusion of weight-loss drugs (see the push to get Medicare to cover GLP-1s) is one example. Employers are another: in KFF's 2025 survey, only 43% of firms with 5,000 or more workers and 16% of firms with 200 to 999 workers covered GLP-1s for weight loss (KFF 2025 Employer Health Benefits Survey (external link)). The same active ingredients are sold under one brand for diabetes (Ozempic, Mounjaro) and another for weight management (Wegovy, Zepbound), so a plan can cover the drug for one condition and exclude it for the other. At least part of that reflects a lingering view of obesity treatment as elective or cosmetic.
The doctor's office. Weight stigma in healthcare, such as blaming unrelated symptoms on weight or giving less thorough care to patients with higher BMIs, is a documented barrier to care that has nothing to do with insurance. Our guide on weight stigma in healthcare settings covers how to advocate for yourself during an appointment.
Friends and family. People who see weight as a matter of willpower may call GLP-1 treatment "the easy way out." See talking to skeptical friends and family for ways to handle those conversations.
Why the framing is worth advocating for
Because the same assumption drives coverage decisions, how clinicians treat patients, and how people react at work and at home, changing it can move all three at once. That's why patient advocacy organizations put effort into this narrative work (see the role of patient advocacy organizations). If you're making the case to an insurer, employer or lawmaker, the Lancet Commission's clinical-obesity criteria give you specific, organ-function-based language to use, which is harder to dismiss than a BMI number.
Study findings above are attributed to their authors and were located via PubMed.
This article is general education, not medical, legal, or insurance advice. Coverage rules, appeal rights, and policy details vary by plan and location and change over time. Confirm specifics with your plan, prescriber, or a qualified advisor.